Literature DB >> 6991327

Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide.

M A Pfeifer, J B Halter, R Graf, D Porte.   

Abstract

To determine how sulfonylureas affect beta cell function, insulin release in response to isoproterenol and arginine was assessed in 32 normal subjects before and during a tolbutamide infusion. When the plasma glucose was allowed to decrease during tolbutamide, the acute insulin response (AIR) to isoproterenol was not changed (delta AIR = 4 +/- 8 MicroU/ml, mean +/- SEM, n = 8,p = NS) and was enhanced slightly for arginine (delta AIR = +61 +/- 26 microU/ml, n = 6, p less than 0.05). When plasma glucose levels were maintained by means of a concomitant variable glucose infusion during tolbutamide, the insulin responses to both isoproterenol and arginine were enhanced (isoproterenol: delta AIR = +55 +/- 15 microU/ml, n = 6, p less than 0.001; arginine: delta AIR = +137 +/- 34 microU/ml, n = 8, p less than 0.001). Regression analysis demonstrated a linear relationship between change in the prestimulus glucose level and the change in the AIR to isoproterenol during tolbutamide (r = 0.66, n = 14, p less than 0.02). Since the slope of his relationship is not significantly different from a similar relationship in the absence of tolbutamide, the potentiating effect of tolbutamide is an amplification of an established physiologic relationship. We conclude that tolbutamide augments the insulin response to nonglucose stimuli. However, this potentiating effect of tolbutamide may be masked by a decrease in the prestimulus glucose level.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6991327     DOI: 10.2337/diab.29.5.335

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Improved effect of glibenclamide on administration before breakfast.

Authors:  G Sartor; I Lundquist; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Lack of primary effect of sulphonylurea (glipizide) on plasma lipoproteins and insulin action in former type 2 diabetics with attenuated insulin secretion.

Authors:  G Sartor; D Ursing; P Nilsson-Ehle; E Wåhlin-Boll; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Oral hypoglycaemic agents. An update.

Authors:  A C Asmal; A Marble
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

4.  Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.

Authors:  E Wåhlin-Boll; L O Almér; A Melander
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

5.  The permissive effect of glucose, tolbutamide and high K+ on arginine stimulation of insulin release in isolated mouse islets.

Authors:  M P Hermans; W Schmeer; J C Henquin
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

6.  Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin.

Authors:  P Serradas; D Bailbé; B Portha
Journal:  Diabetologia       Date:  1989-08       Impact factor: 10.122

7.  The regulation of glucose-induced insulin secretion by pre-stimulus glucose level and tolbutamide in normal man.

Authors:  M A Pfeifer; R J Graf; J B Halter; D Porte
Journal:  Diabetologia       Date:  1981-09       Impact factor: 10.122

8.  Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.

Authors:  J P Hosker; M A Burnett; E G Davies; E A Harris; R C Turner
Journal:  Diabetologia       Date:  1985-11       Impact factor: 10.122

9.  Molecular characterization of a local sulfonylurea system in human adipose tissue.

Authors:  Britt G Gabrielsson; A Cecilia Karlsson; Malin Lönn; Louise E Olofsson; Jenny M Johansson; Jarl S Torgerson; Lars Sjöström; Björn Carlsson; Staffan Edén; Lena M S Carlsson
Journal:  Mol Cell Biochem       Date:  2004-03       Impact factor: 3.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.